SCHEMBL4850106

SCHEMBL4850106

COC(=O)c1ccc2cc[c]cc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 3/20 0.36
CYP1A2 P05177 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CNR2 P34972 1/20 0.36
GAA P10253 1/20 0.36
RECQL P46063 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28347669 0.87 MAPK1 (0.40) MAPK1ALDH1A1HPGDKDM4EHTT
SCHEMBL5776009 0.81 MGAM (0.38) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL15515476 0.80 MGAM (0.56) ALDH1A1HPGDKDM4EL3MBTL1KMT2A
SCHEMBL15516376 0.78 PIM1 (0.41) ALDH1A1KDM4EKMT2AMAPTSMN1; SMN2
SCHEMBL725183 0.76 MGAM (0.61) ALDH1A1HPGDKDM4EHTTABCG2
SCHEMBL30208641 0.76 MGAM (0.61) ALDH1A1HPGDKDM4EHTTABCG2
Hydrochloric Acid SCHEMBL16793838 0.75 MGAM (0.59) ALDH1A1HPGDKDM4EHTTABCG2
Hydrochloric Acid SCHEMBL30615167 0.75 MGAM (0.59) ALDH1A1HPGDKDM4EHTTABCG2
SCHEMBL9222973 0.74 MAPK1 (0.46) MAPK1ALDH1A1HPGDKDM4EHTT
SCHEMBL18572013 0.73 CA12 (0.47) MAPK1ALDH1A1HPGDKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
EP-1670794-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2006-06-21 EP disclosed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US disclosed
WO-2005033105-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 MAPK1 1561/4885ALDH1A1 3253/4885HPGD 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.